Intellia Therapeutics

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.

Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.

We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

AWARDS
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • Intellia Top places to work
  • 2022 Best Places to Work
  • Intellia 2022 BG top places
40 Erie Street
Cambridge, MA 02139
Stock Symbol: NTLA
  • Featured Employer
At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop CRISPR one-time treatments.
Tune into our podcast, Imagine the Possibilities, where we showcase Intellia talent across departments and take deep dives into all things culture and careers. We talk about career steps (and missteps), development, growth, and more. Just imagine the possibilities of what we can learn together.
Employee Testimonials
  • “Diversity, Equity and Inclusion is really important to me because in order to deliver our drugs to patients and achieve our goals, we need to create a work environment where everybody – regardless of race, gender, or sexuality – can come to Intellia and succeed here. That is what the Employee Resource Groups do, and that is why it is so important that Intellia has this program.”
    Peter C. Associate Scientist
  • “I lead the Community, Wellness, and Sustainability Cultural Ambassadors Team and am deeply passionate about the environment and wellness from a holistic point of view. As a team, we raise awareness on topics like plastic pollution, sustainable living, and climate change. We motivate others to adopt simple, yet impactful adjustments to their lifestyle and promote healthy work-life balance by offering weekly practices such as yoga, mindfulness and meditation.”
    Elena K, Sr Scientist, RNA Chemistry & Delivery Sciences
  • “There have been an immense number of opportunities for me to step up and make meaningful contributions to Intellia’s vision. I’ve been surrounded by career role models thoughout my time here. I learn from their career growth and apply those learnings to my own journey.”
    Ramsey M, Director, Delivery Sciences, Delivery Physics, and Biology
NEWS
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.
On Monday, LogicBio Therapeutics unveiled clinical trial results demonstrating the first-ever in vivo, nuclease-free genome editing in little humans.
Genome-editing company Intellia Therapeutics and France-based SparingVision have partnered to develop new therapies for ocular diseases. The deal could be worth up to $600 million for Intellia.
Another busy week for clinical trial news. Here’s a look.
EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.
NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML).
On June 26, Intellia announced the first-ever clinical data supporting the safety and efficacy of in vivo CRISPR genome editing in human patients.
JOBS
  • Intellia 2025 Premier
  • Intellia 2024 Elite artwork
IN THE PRESS